In this review of romiplostim, a second- generation thrombopoietic agent that stimulates the thrombopoietin receptor and platelet production without inducing production of autoantibodies, the authors examine the following:

• Pharmacology

• Pharmacokinetics

• Dosage and administration

• Efficacy

• Health-related quality of life in ITP

• Safety

• Cost

• Place in therapy

In February 2009, Amgen received marketing authorisation from the European Medicines Agency for romiplostim (Nplate®) for the treatment of splenectomised adults with chronic ITP who are refractory to other treatments